Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Xiaobing Wang(Shanghai Changzheng Hospital), Huji Xu(University of Science and Technology of China), Miaozhen Huang(Tsinghua University), Lin Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Du(Capital Institute of Pediatrics), Jian Zhu(Zhejiang Medicine (China)), Xinyi Wan(University of Science and Technology of China), Le‐Hang Guo(Tongji University), Binghe Tan(East China Normal University), Huaxiang Wu(Second Affiliated Hospital of Zhejiang University), D. Li(East China Normal University), Na Ta(Second Military Medical University), Xiaoming Pan(Shanghai Changzheng Hospital), Shiyuan Liu(Shanghai Changzheng Hospital), Jianfeng Chen(Sun Yat-sen University), Yi Zhang(Tianjin Medical University General Hospital), Hang Zhang(Shanghai Changzheng Hospital), Ling Zhou(Yibin University), Lingyun Sun(Anhui Medical University), Yanfang Liu(Second Military Medical University), Mingyao Liu(East China Normal University), Yi Jin(China Pharmaceutical University), Biao Zheng(Shanghai Cell Therapy Research Institute), Hongjuan Lu(Shanghai Changzheng Hospital), Hui Cheng(Wenzhou Medical University), Liang Zhu(Second Affiliated Hospital of Zhejiang University), Weiqing Li(Shanghai Changzheng Hospital), Yi Xiao(Tongji Hospital), Ping Wang(Feinstein Institute for Medical Research), Yanran He(University of Chicago), Jialin Song(Qingdao University), Wenjing Ye(Huashan Hospital), Lingying Ye(Second Military Medical University), Jian Yin(Shanghai Changzheng Hospital), An Sun(Shanghai Changzheng Hospital), Ting Li(Zhejiang Chinese Medical University), Jinwei Hong(Wenzhou Medical University), Jing Luo(Tsinghua University), Lie Dai(Sun Yat-sen University), Jin Zhang(Stomatology Hospital), Xinyu Wu(Heilongjiang University of Chinese Medicine)
Cited by 272
Related Papers
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
|The Lancet|2020|29.1k
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
|New England Journal of Medicine|2020|5.5k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Roles of IFN-γ in tumor progression and regression: a review
|Biomarker Research|2020|1.2k